List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8710979/publications.pdf Version: 2024-02-01



YOSHIHIDE HEDA

#	Article	IF	CITATIONS
1	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	3.7	21
2	Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization. Cancer Research, 2022, 82, 1712-1723.	0.9	7
3	Acidâ€treated highâ€amylose corn starch suppresses highâ€fat dietâ€induced steatosis. Journal of Food Science, 2022, , .	3.1	1
4	Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing. Scientific Reports, 2022, 12, 7083.	3.3	3
5	Allograft liver failure awaiting liver transplantation in Japan. Journal of Gastroenterology, 2022, 57, 495-504.	5.1	2
6	Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis. Clinical Journal of Gastroenterology, 2021, 14, 293-296.	0.8	1
7	Liver abscess caused by Cutibacterium namnetense after transarterial chemoembolization for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 246-250.	0.8	5
8	Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1747-1756.	2.5	11
9	Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus. Carcinogenesis, 2021, 42, 672-684.	2.8	6
10	Jejunal variceal rupture in a patient with myelofibrosis: a case report. Clinical Journal of Gastroenterology, 2021, 14, 542-545.	0.8	0
11	Beta-catenin-activated hepatocellular adenoma in a male. Clinical Journal of Gastroenterology, 2021, 14, 831-835.	0.8	1
12	Hepatitis-associated Aplastic Anemia with Rapid Progression of Liver Fibrosis Due to Repeated Hepatitis. Internal Medicine, 2020, 59, 1035-1040.	0.7	1
13	Use of Nakanuma staging and cytokeratinÂ7 staining for diagnosing recurrent primary biliary cholangitis after livingâ€donor liver transplantation. Hepatology Research, 2020, 50, 478-487.	3.4	5
14	Multiregional wholeâ€genome sequencing of hepatocellular carcinoma with noduleâ€inâ€nodule appearance reveals stepwise cancer evolution. Journal of Pathology, 2020, 252, 398-410.	4.5	15
15	DNA methyltransferase 3B plays a protective role against hepatocarcinogenesis caused by chronic inflammation via maintaining mitochondrial homeostasis. Scientific Reports, 2020, 10, 21268.	3.3	7
16	Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome. Scientific Reports, 2020, 10, 2651.	3.3	14
17	New sequencing technology, thirdâ€generation nanopore sequencing, for hepatitis C virus research. Hepatology Research, 2019, 49, 961-963.	3.4	3
18	Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancers, 2019, 11, 405.	3.7	22

#	Article	IF	CITATIONS
19	Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12Âweeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. Journal of Gastroenterology, 2019, 54, 660-666.	5.1	16
20	Utility of ultrasoundâ€guided liver tumor biopsy for nextâ€generation sequencingâ€based clinical sequencing. Hepatology Research, 2019, 49, 579-589.	3.4	6
21	Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis. Internal Medicine, 2019, 58, 67-71.	0.7	3
22	Exploring the hepatitis C virus genome using single molecule real-time sequencing. World Journal of Gastroenterology, 2019, 25, 4661-4672.	3.3	11
23	Association of Macâ€2â€binding protein glycosylation isomer level with nutritional status in chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1649-1658.	2.8	6
24	Impact of Donor Age on Recipient Survival in Adult-to-Adult Living-donor Liver Transplantation. Annals of Surgery, 2018, 267, 1126-1133.	4.2	63
25	Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection. Scientific Reports, 2018, 8, 18070.	3.3	14
26	The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of antiâ€ <scp>HB</scp> c–positive livers. Pediatric Transplantation, 2018, 22, e13227.	1.0	9
27	Successful endoscopic removal of fractured guidewire fragments from a peripheral bile duct using a biliary stent delivery system and biopsy forceps. Endoscopy, 2018, 50, E279-E280.	1.8	6
28	Ultrasoundâ€guided microfoam sclerotherapy with polidocanol for symptomatic giant hepatic cyst: Initial experience. Hepatology Research, 2018, 48, 1055-1063.	3.4	3
29	Treatment with sofosbuvir and ledipasvir without ribavirin for 12Âweeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. Journal of Gastroenterology, 2017, 52, 986-991.	5.1	28
30	Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Scientific Reports, 2017, 7, 45605.	3.3	20
31	Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c. Digestion, 2017, 96, 228-230.	2.3	21
32	Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience. Clinical Transplantation, 2017, 31, e13109.	1.6	12
33	Hepatobiliary and Pancreatic: Granulomatous hepatitis due to disseminated bacillus Calmette-Guérin disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1538-1538.	2.8	1
34	Hepatitis B virus genotype E infection among Egyptian health care workers. Journal of Translational Internal Medicine, 2017, 5, 100-105.	2.5	14
35	The role of hepatologists in liver transplantation; the results of questionnaire survey for institutions belonging to the Japanese Liver Transplantation Society. Acta Hepatologica Japonica, 2017, 58, 97-104.	0.1	0
36	Two cases of granulomatous hepatitis due to disseminated bacillus Calmette-Guérin (BCC) disease. Acta Hepatologica Japonica, 2017, 58, 406-414.	0.1	2

#	Article	IF	CITATIONS
37	Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience. Transplantation Direct, 2017, 3, e334.	1.6	30
38	Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients. Transplantation, 2016, 100, 54-60.	1.0	9
39	Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after livingâ€donor liver transplantation: A Japanese multicenter experience. Hepatology Research, 2016, 46, 1285-1293.	3.4	7
40	Sonazoid-enhanced ultrasonography guidance improves the quality of pathological diagnosis in the biopsy of focal hepatic lesions. European Journal of Gastroenterology and Hepatology, 2016, 28, 1462-1467.	1.6	19
41	<i>TERT</i> promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver diseaseâ€related hepatocellular carcinoma. International Journal of Cancer, 2016, 139, 2512-2518.	5.1	36
42	Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. Transplant International, 2016, 29, 119-121.	1.6	12
43	Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatology Research, 2016, 46, 541-551.	3.4	12
44	Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation. Transplant International, 2015, 28, 251-252.	1.6	8
45	Slow Progression of Poorly Differentiated Gastric Carcinoma Associated with Epstein-Barr Virus Infection: 12-year Follow-up. Internal Medicine, 2015, 54, 1505-1508.	0.7	Ο
46	Generalized morphea with preceding severe pain and coexistent early primary biliary cirrhosis. European Journal of Dermatology, 2015, 25, 365-366.	0.6	6
47	Spontaneous clearance of hepatitis C virus after liver transplantation: a report of four cases. Surgical Case Reports, 2015, 1, 124.	0.6	3
48	Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatology Research, 2015, 45, 1360-1362.	3.4	9
49	Lateâ€onset acetaminophenâ€induced allergic hepatitis with progression to chronicity. Hepatology Research, 2015, 45, 814-817.	3.4	4
50	Plasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis <scp>C</scp> after living donor liver transplantation. Hepatology Research, 2014, 44, E279-83.	3.4	4
51	Significance of pretransplant abstinence on harmful alcohol relapse after liver transplantation for alcoholic cirrhosis in <scp>J</scp> apan. Hepatology Research, 2014, 44, E428-36.	3.4	23
52	Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. Journal of Hepatology, 2014, 61, 492-501.	3.7	22
53	Successful Telaprevir Treatment in Combination of Cyclosporine against Recurrence of Hepatitis C in the Japanese Liver Transplant Patients. Biological and Pharmaceutical Bulletin, 2014, 37, 417-423.	1.4	7
54	Chronic Rejection Associated with Antiviral Therapy for Recurrent Hepatitis C after Living-Donor Liver Transplantation. Transplantation, 2014, 97, 344-350.	1.0	10

#	Article	IF	CITATIONS
55	Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after livingâ€donor liver transplantation. Hepatology Research, 2013, 43, 67-71.	3.4	37
56	Dynamics of Defective Hepatitis C Virus Clones in Reinfected Liver Grafts in Liver Transplant Recipients: Ultradeep Sequencing Analysis. Journal of Clinical Microbiology, 2013, 51, 3645-3652.	3.9	14
57	Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. PLoS ONE, 2013, 8, e58380.	2.5	1
58	Dynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing. PLoS ONE, 2012, 7, e35052.	2.5	76
59	Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. Journal of Gastroenterology, 2012, 47, 444-451.	5.1	46
60	Effect of maintenance therapy with lowâ€dose peginterferon for recurrent hepatitis C after living donor liver transplantation. Journal of Viral Hepatitis, 2012, 19, 32-38.	2.0	4
61	Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. International Journal of Cancer, 2012, 130, 1294-1301.	5.1	37
62	Frequent overlap of active hepatitis in recurrent primary sclerosing cholangitis after living-donor liver transplantation relates to its rapidly progressive course. Human Pathology, 2011, 42, 1329-1336.	2.0	8
63	<i>De novo</i> activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antiviral Therapy, 2011, 16, 479-487.	1.0	29
64	Risk Factors for Recurrence of Primary Sclerosing Cholangitis after Living Donor Liver Transplantation in Japanese Registry. American Journal of Transplantation, 2011, 11, 518-527.	4.7	72
65	Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective Study. Digestion, 2011, 84, 43-49.	2.3	22
66	Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing. PLoS ONE, 2011, 6, e24907.	2.5	86
67	Individualized Extension of Pegylated Interferon Plus Ribavirin Therapy for Recurrent Hepatitis C Genotype 1b After Living-Donor Liver Transplantation. Transplantation, 2010, 90, 661-665.	1.0	22
68	Spontaneous Rupture of Liver Plasmacytoma Mimicking Hepatocellular Carcinoma. Internal Medicine, 2010, 49, 653-657.	0.7	11
69	<i>De novo</i> hepatitis B virus infection in hepatocellular carcinoma following eradication of hepatitis C virus by interferon therapy. Hepatology Research, 2010, 40, 661-665.	3.4	1
70	Simultaneous Occurrence of Inflammatory Bowel Disease and Myelodysplastic Syndrome due to Chromosomal Abnormalities in Bone Marrow Cells. Digestion, 2009, 79, 215-219.	2.3	11
71	Effective treatment for <i>de novo</i> hepatitis B with nucleotide analogue in patients with hematological malignancies. American Journal of Hematology, 2009, 84, 315-316.	4.1	2
72	Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. Journal of Gastroenterology, 2009, 44, 359-364.	5.1	32

#	Article	IF	CITATIONS
73	Risk Factors for Recurrence of Primary Sclerosing Cholangitis After Living Donor Liver Transplantation: A Single Center Experience. Digestive Diseases and Sciences, 2009, 54, 1347-1354.	2.3	55
74	Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation. Journal of Viral Hepatitis, 2009, 17, 481-7.	2.0	6
75	Colonic Polyposis Associated With Autoimmune Pancreatitis. Pancreas, 2009, 38, 840-842.	1.1	8
76	Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation. Liver Transplantation, 2008, 14, 1044-1047.	2.4	15
77	Organâ€specific profiles of genetic changes in cancers caused by activationâ€induced cytidine deaminase expression. International Journal of Cancer, 2008, 123, 2735-2740.	5.1	80
78	Helicobacter pylori in solid-organ transplant recipient. Current Opinion in Organ Transplantation, 2008, 13, 586-591.	1.6	7
79	Limited Benefit of Biochemical Response to Combination Therapy for Patients With Recurrent Hepatitis C After Living-Donor Liver Transplantation. Transplantation, 2008, 85, 855-862.	1.0	18
80	Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. International Journal of Cancer, 2007, 120, 469-476.	5.1	117
81	Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nature Genetics, 2007, 39, 391-396.	21.4	308
82	Gastrointestinal: Ileal ulcers induced by non-steroidal anti-inflammatory drugs. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1346-1346.	2.8	0
83	Expression of APOBEC2 is transcriptionally regulated by NF-κB in human hepatocytes. FEBS Letters, 2006, 580, 731-735.	2.8	27
84	Anti-viral protein APOBEC3G is induced by interferon- $\hat{l}\pm$ stimulation in human hepatocytes. Biochemical and Biophysical Research Communications, 2006, 341, 314-319.	2.1	127
85	Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. Development (Cambridge), 2006, 133, 1183-1192.	2.5	150
86	Inactivation of Dnmt3b in Mouse Embryonic Fibroblasts Results in DNA Hypomethylation, Chromosomal Instability, and Spontaneous Immortalization. Journal of Biological Chemistry, 2005, 280, 17986-17991.	3.4	237
87	Diverse p53 gene aberration in hepatocellular carcinoma detected by dual-color fluorescence in situ hybridization. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1066-1073.	2.8	2
88	Suv39h-Mediated Histone H3 Lysine 9 Methylation Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin. Current Biology, 2003, 13, 1192-1200.	3.9	1,090
89	Establishment and Maintenance of Genomic Methylation Patterns in Mouse Embryonic Stem Cells by Dnmt3a and Dnmt3b. Molecular and Cellular Biology, 2003, 23, 5594-5605.	2.3	652
90	A Novel Dnmt3a Isoform Produced from an Alternative Promoter Localizes to Euchromatin and Its Expression Correlates with Activede Novo Methylation. Journal of Biological Chemistry, 2002, 277, 38746-38754.	3.4	302

#	Article	IF	CITATIONS
91	RelA suppresses the Wnt/β-catenin pathway without exerting trans-acting transcriptional ability. International Journal of Molecular Medicine, 2002, 9, 489.	4.0	4
92	Wnt/?-catenin signaling suppresses apoptosis in low serum medium and induces morphologic change in rodent fibroblasts. International Journal of Cancer, 2002, 99, 681-688.	5.1	31
93	p73β, a Variant of p73, Enhances Wnt/β-Catenin Signaling in Saos-2 Cells. Biochemical and Biophysical Research Communications, 2001, 283, 327-333.	2.1	22
94	Overproduced p73 \hat{I} ± activates a minimal promoter through a mechanism independent of its transcriptional activity. FEBS Letters, 2001, 509, 47-52.	2.8	6
95	Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochemical Journal, 2001, 356, 859.	3.7	15
96	Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochemical Journal, 2001, 356, 859-866.	3.7	26
97	Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen. Journal of Gastroenterology, 2001, 36, 633-636.	5.1	27
98	Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology, 2000, 31, 488-495.	7.3	230
99	Functional impairment of p73 and p51, the p53-related proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein. Oncogene, 2000, 19, 827-830.	5.9	34
100	Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplantation, 2000, 25, 105-108.	2.4	71
101	New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene, 1999, 18, 4993-4998.	5.9	138
102	Islet-cell hyperplasia causing hyperinsulinemic hypoglycemia in an adult. Journal of Gastroenterology, 1998, 33, 125-128.	5.1	10
103	A Functioning Black Adenoma of the Adrenal Gland Internal Medicine, 1997, 36, 398-402.	0.7	15